Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Brain-derived neurotrophic factor (BDNF) activates the receptor tropomyosin-related kinase B (TrkB) with high potency and specificity, promoting neuronal survival, differentiation, and synaptic function. Correlations between altered BDNF expression and/or function and mechanism(s) underlying numerous neurodegenerative conditions, including Alzheimer disease and traumatic brain injury, suggest that TrkB agonists might have therapeutic potential. Using in silico screening with a BDNF loop-domain pharmacophore, followed by low-throughput in vitro screening in mouse fetal hippocampal neurons, we have efficiently identified small molecules with nanomolar neurotrophic activity specific to TrkB versus other Trk family members. Neurotrophic activity was dependent on TrkB and its downstream targets, although compound-induced signaling activation kinetics differed from those triggered by BDNF. A selected prototype compound demonstrated binding specificity to the extracellular domain of TrkB. In in vitro models of neurodegenerative disease, it prevented neuronal degeneration with efficacy equal to that of BDNF, and when administered in vivo, it caused hippocampal and striatal TrkB activation in mice and improved motor learning after traumatic brain injury in rats. These studies demonstrate the utility of loop modeling in drug discovery and reveal what we believe to be the first reported small molecules derived from a targeted BDNF domain that specifically activate TrkB.We propose that these compounds constitute a novel group of tools for the study of TrkB signaling and may provide leads for developing new therapeutic agents for neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LM22A-4 was designed to mimic the loop II domain of BDNF and proven to be a partial agonist.”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Massa et al. 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In vitro work showed that LM22A-4 has neuroprotective properties (Massa et al. 2010).”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Massa et al. 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
Neurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944
Virtual screening of chemical libraries
Shoichet, B. K. (2004) · Nature · doi:10.1038/nature03197 · Cited by 1,425
Ageing and neuronal vulnerability
Mattson, M. P., & Magnus, T. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1886 · Cited by 957
Sairanen, M., Lucas, G., Ernfors, P., Castrén, M., & Castrén, E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3741-04.2005 · Cited by 763
TrkB Regulates Hippocampal Neurogenesis and Governs Sensitivity to Antidepressive Treatment
Li, Y., Luikart, B. W., Birnbaum, S., Chen, J., Kwon, C.-H., Kernie, S. G., Bassel-Duby, R., & Parada, L. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.023 · Cited by 634
Poduslo, J. F., & Curran, G. L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00250-v · Cited by 614
Research works printed but not linked: 1
- Conte, 2008, Restor Neurol Neurosci., 26, 45
Cited by
Bridging animal and human models of exercise-induced brain plasticity
Voss, M. W., Vivar, C., Kramer, A. F., & van Praag, H. (2013) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2013.08.001 · Cited by 1,030
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867
“; and by developing peptide mimetics of growth factors with specificity for degenerating cell system”
BackgroundGDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
“After administration in vivo to rats with traumatic brain injury, improvement was seen in motor learning (Massa et al., 2010).”
BackgroundBDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3505 · Cited by 743
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
“inducing differentiation and augmenting synaptic function (Massa et al., 2010).”
Modarresi, F., Faghihi, M. A., Lopez-Toledano, M. A., Fatemi, R. P., Magistri, M., Brothers, S. P., van der Brug, M. P., & Wahlestedt, C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2158 · Cited by 668
BDNF signaling in context: From synaptic regulation to psychiatric disorders
Wang, C. S., Kavalali, E. T., & Monteggia, L. M. (2022) · Cell · doi:10.1016/j.cell.2021.12.003 · Cited by 607
BDNF mediates adaptive brain and body responses to energetic challenges
Marosi, K., & Mattson, M. P. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.10.006 · Cited by 568
“Molecular modeling and evaluation of more than 1 million chemicals, indentified top ‘hits’ with neuroprotective actions in cultured neurons, and resulted in the identification of several low molecular weight BDNF mimetics [74].”
BackgroundNeurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders
Notaras, M., & van den Buuse, M. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0639-2 · Cited by 392
Cazorla, M., Prémont, J., Mann, A., Girard, N., Kellendonk, C., & Rognan, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43992 · Cited by 392
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“Although poor blood–brain-barrier permeability (Wu, 2005) limits the therapeutic potential of BDNF itself, TrkB receptor agonists such as DHF (see above) or LM22A-4 (Massa et al., 2010) may hold promise for CBT-adjunctive therapy in anxiety.”
BackgroundTen things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
“Other examples of kinase activators include a mimetic of the brain-derived neurotrophic factor that activates TrkB [tropomyosin receptor kinase B or neurotrophin receptor kinase-2 (NTRK-2)] (Massa et al., 2010).”
BackgroundEngineering mesenchymal stem cells to improve their exosome efficacy and yield for cell‐free therapy
Phan, J., Kumar, P., Hao, D., Gao, K., Farmer, D., & Wang, A. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1522236 · Cited by 333
Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308
Longo, F. M., & Massa, S. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4024 · Cited by 298
Self-citationLoss of adaptive myelination contributes to methotrexate chemotherapy-related cognitive impairment
Geraghty, A. C., Gibson, E. M., Ghanem, R. A., Greene, J. J., Ocampo, A., Goldstein, A. K., Ni, L., Yang, T., Marton, R. M., Paşca, S. P., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.04.032 · Cited by 288
“neurodegenerative disorders, LM22A-4 achieves Bdnf-type-trophic effects including promotion of neuronal survival and neurogenesis, and modulation of neuronal activity (Massa et al., 2010; Han et al., 2012; Li et al., 2017).”
BackgroundSelf-citationEpigenetic Regulation of the BDNF Gene: Implications for Psychiatric Disorders
Boulle, F., van den Hove, D. L. A., Jakob, S. B., Rutten, B. P., Hamon, M., van Os, J., Lesch, K.-P., Lanfumey, L., Steinbusch, H. W., & Kenis, G. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.107 · Cited by 282
Fear extinction and BDNF: translating animal models of PTSD to the clinic
Andero, R., & Ressler, K. J. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00801.x · Cited by 276
“LM22A-4 appears to be another potential TrkB agonist, which when chronically administered intranasally in rodents crosses the BBB and activates its downstream signalling (Massa et al. 2010).”
BackgroundTrkB Receptor Signalling: Implications in Neurodegenerative, Psychiatric and Proliferative Disorders
Gupta, V., You, Y., Gupta, V., Klistorner, A., & Graham, S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140510122 · Cited by 258
“to be in equilibrium with the phosphorylated dimeric state [2].”
BackgroundThe neuroprotective roles of BDNF in hypoxic ischemic brain injury
CHEN, A., XIONG, L.-J., TONG, Y., & MAO, M. (2013) · Biomedical Reports · doi:10.3892/br.2012.48 · Cited by 267
“Mature BDNF binds with high specificity to the tropomyosin‑related kinase receptor type B (TrkB) (26) and to the low‑affinity neurotrophin receptor p75, then exerts its actions via interactions between these two trans-membrane receptors, separately or in collectively, potentially leading to…”
The Aging Eye: Common Degenerative Mechanisms Between the Alzheimer's Brain and Retinal Disease
Sivak, J. M. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10827 · Cited by 220
The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12449 · Cited by 221
Current advances in using neurotrophic factors to treat neurodegenerative disorders
Weissmiller, A. M., & Wu, C. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-14 · Cited by 211
“When administered to mouse models of AD, Huntington, and PD, the small molecule was able to rescue cellular death to the same extent of full protein BDNF [70].”
BackgroundMethodBrain-Derived Neurotrophic Factor and Alzheimer’s Disease: Physiopathology and Beyond
Diniz, B. S., & Teixeira, A. L. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8154-x · Cited by 201
Andero, R., Choi, D. C., & Ressler, K. J. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-420170-5.00006-4 · Cited by 182
The role of BDNF in Alzheimer's disease
Tanila, H. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.008 · Cited by 185
“The compound also improved motor learning after traumatic brain injury in rats (Massa et al., 2010).”
BackgroundRothman, S. M., & Mattson, M. P. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.10.014 · Cited by 183
“One such molecule, termed LM22A-4, showed efficacy in improving both breathing frequency and levels of TrkB phosphorylation in a mouse model of Rett syndrome (Massa et al., 2010; Schmid et al., 2012).”
InfluentialThe Neurotrophins and Their Role in Alzheimers Disease
J. Allen, S., J. Watson, J., & Dawbarn, D. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376190 · Cited by 177
“In addition small molecule mimetics of NGF or BDNF have also been suggested as Alzheimer therapeutics [180, 181].”
BackgroundBDNF deregulation in Rett syndrome
Li, W., & Pozzo-Miller, L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.024 · Cited by 175
“Another promising compound is the BDNF mimetic LM22A-4, which selectively activates TrkB but not other Trk family members (Massa et al., 2010).”
BackgroundCHEN, A., XIONG, L.-J., TONG, Y., & MAO, M. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1628 · Cited by 174
“The effects of BDNF are mediated via binding to its specific receptors, tyrosine kinase B (TrkB) and p75 (4,5).”
InfluentialRecruiting adaptive cellular stress responses for successful brain ageing
Stranahan, A. M., & Mattson, M. P. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3151 · Cited by 169
“Because neurotrophic factors may not readily cross the blood–brain barrier, there are efforts to develop low-molecular-weight agonists of neurotrophic factors with high specificity and potenc”
BackgroundBrain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities
Liu, W., Wang, X., O’Connor, M., Wang, G., & Han, F. (2020) · Neural Plasticity · doi:10.1155/2020/1969482 · Cited by 160
“performed intranasal administration of LM22A4, in in vitro neurodegenerative disease models to promote cell survival, and in a rat parietal CCI model to reduce neuronal cell death [115].”
MethodInnovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF
Mitra, S., Behbahani, H., & Eriksdotter, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00038 · Cited by 159
Bastioli, G., Arnold, J. C., Mancini, M., Mar, A. C., Gamallo‐Lana, B., Saadipour, K., Chao, M. V., & Rice, M. E. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.2273-21.2022 · Cited by 166
Schmid, D. A., Yang, T., Ogier, M., Adams, I., Mirakhur, Y., Wang, Q., Massa, S. M., Longo, F. M., & Katz, D. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0865-11.2012 · Cited by 152
“LM22A-4 was developed by Longo, Massa and colleagues by in silico screening for mimetics of BDNF loop domains that selectively activate TrkB in vitro and in vivo and promote recovery of motor function in a rodent model of brain trauma (Massa et al., 2010).”
BackgroundResultInfluentialSelf-citationTrkB/BDNF signaling pathway and its small molecular agonists in CNS injury
Wang, Y., Liang, J., Xu, B., Yang, J., Wu, Z., & Cheng, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122282 · Cited by 152
Giacoppo, S., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.11.010 · Cited by 155
“BDNF via binding to its specific receptors, tyrosine kinase B (TrkB) and p75 [38,39] triggers intracellular signaling cascades, including PI3K/ Akt/mTOR pathway [40].”
BackgroundGupta, V., You, Y., Li, J., Gupta, V. B., Golzan, M., Klistorner, A. I., van den Buuse, M., & Graham, S. L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.026 · Cited by 155
“b BDNF loss has previously been shown to associate with decreased activation of TrkB and downstream pro-survival signalling pathways [56].”
BackgroundBDNF signaling during the lifetime of dendritic spines
Zagrebelsky, M., Tacke, C., & Korte, M. (2020) · Cell and Tissue Research · doi:10.1007/s00441-020-03226-5 · Cited by 147
Simmons, D. A., Belichenko, N. P., Yang, T., Condon, C., Monbureau, M., Shamloo, M., Jing, D., Massa, S. M., & Longo, F. M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1310-13.2013 · Cited by 144
“Our laboratories identified small molecule TrkB ligands with structures similar to loop II of BDNF (Massa et al., 2010), a region that confers TrkB activation and specificity (Longo and Massa, 2013).”
BackgroundMethodResultSelf-citationYip, P. K., Carrillo-Jimenez, A., King, P., Vilalta, A., Nomura, K., Chau, C. C., Egerton, A. M. S., Liu, Z.-H., Shetty, A. J., Tremoleda, J. L., et al. (2017) · Scientific Reports · doi:10.1038/srep41689 · Cited by 138
25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations
Fabbro, D. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.095489 · Cited by 152
Balaratnasingam, S., & Janča, A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.006 · Cited by 148
Jiang, M., Peng, Q., Liu, X., Jin, J., Hou, Z., Zhang, J., Mori, S., Ross, C. A., Ye, K., & Duan, W. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt098 · Cited by 129
“For example, small-molecule BDNF mimetics identified by in silico screening with a BDNF loopdomain pharmacophore, followed by low-throughput in vitro screening in mouse fetal hippocampal neurons, have been shown to prevent neuronal degeneration in rodents (52) and improved respiratory function in a mouse model of Rett…”
BackgroundAberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease
Camandola, S., & Mattson, M. P. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.10.005 · Cited by 119
Fletcher, J. L., Murray, S. S., & Xiao, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124131 · Cited by 138
Kazim, S. F., & Iqbal, K. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0119-y · Cited by 115
“A BDNF small-molecule mimetic compound, LM22A-4, identified using in silico screening with a BDNF loop-domain pharmacophore, was found to promote survival of hippocampal neurons (~85 % of the efficacy of BDNF), induce TrkB phosphorylation, and prevent neuronal death in an in vitro model of AD [168].”
BackgroundGéral, C., Angelova, A., & Lesieur, S. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5010127 · Cited by 123
“Prodrugs of non-peptide neurotrophin mimetics non-peptide mimetics of BDNF Psychiatric disorders Mice reduced depression- and anxiety-related behaviors; blood-brain barrier penetration [213,215]”
BackgroundMolecular mechanisms of brain-derived neurotrophic factor in neuro-protection: Recent developments
Zhao, H., Alam, A., San, C.-Y., Eguchi, S., Chen, Q., Lian, Q., & Ma, D. (2017) · Brain Research · doi:10.1016/j.brainres.2017.03.029 · Cited by 122
Numakawa, T., & Kajihara, R. (2025) · Molecules · doi:10.3390/molecules30040848 · Cited by 126
“LM22A-4 demonstrated promising neuroprotective properties in animal models, including the promotion of neuronal survival, enhanced synaptic plasticity, and improved cognitive outcomes in rodent models of neurodegeneration including AD [87,88].”
Liu, X., Obianyo, O., Chan, C. B., Huang, J., Xue, S., Yang, J. J., Zeng, F., Goodman, M., & Ye, K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.562561 · Cited by 113
“These hypotheses might apply to many of the most recently identified small TrkB agonists (14, 15, 57).”
BackgroundNeuroprotective effect of curcumin on hippocampal injury in 6-OHDA-induced Parkinson's disease rat
Yang, J., Song, S., Li, J., & Liang, T. (2014) · Pathology - Research and Practice · doi:10.1016/j.prp.2014.02.005 · Cited by 122
Alzheimer disease therapeutics: Focus on the disease and not just plaques and tangles
Iqbal, K., Liu, F., & Gong, C.-X. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.002 · Cited by 109
Targeting BDNF/TrkB pathways for preventing or suppressing epilepsy
Lin, T. W., Harward, S. C., Huang, Y. Z., & McNamara, J. O. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107734 · Cited by 117
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript One issue warranting careful consideration is the possibility that the effects of LM22A-4 are mediated by a target distinct from TrkB.”
BackgroundMethodInfluentialCastello, N. A., Nguyen, M. H., Tran, J. D., Cheng, D., Green, K. N., & LaFerla, F. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091453 · Cited by 113
“Since BDNF has poor blood-brain barrier penetration and a short half life [14], TrkB has typically been targeted by locally upregulating BDNF through viral overexpression or direct protein infusion [6,7,15].”
BackgroundInfluentialWu, C.-H., Hung, T.-H., Chen, C.-C., Ke, C.-H., Lee, C.-Y., Wang, P.-Y., & Chen, S.-F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113397 · Cited by 108
“TrkB activation prevents neuronal degeneration in various in vitro models of neuronal insults [15], [31], [32].”
BackgroundOuaamari, Y. E., den Bos, J. V., Willekens, B. M. P., Cools, N., & Wens, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043866 · Cited by 119
(2018) · doi:10.1038/s41467-018-06675-3 · Cited by 111
Long-lasting effects of chronic rTMS to treat chronic rodent model of depression
Feng, S., Shi, T., FanYang, Wang, W.-N., Chen, Y.-C., & Tan, Q. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.04.019 · Cited by 115
Smith, P. A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.05.044 · Cited by 118
“The observation by Pitcher and Henry (2008) that application of lidocaine to injured peripheral nerves in vivo reduced the elevated discharge rate of single, secondorder wide dynamic range neurons in the spinal cord underlined a role for peripheral sensitization in the etiology of neuropathic pain.”
BackgroundWu, C.-C., Lien, C.-C., Hou, W.-H., Chiang, P.-M., & Tsai, K.-J. (2016) · Scientific Reports · doi:10.1038/srep27358 · Cited by 104
Edelbrock, A. N., Àlvarez, Z., Simkin, D., Fyrner, T., Chin, S. M., Sato, K., Kiskinis, E., & Stupp, S. I. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02317 · Cited by 103
Back to the Future with Phenotypic Screening
Prior, M., Chiruta, C., Currais, A. J. M., Goldberg, J., Ramsey, J., Dargusch, R., Maher, P. A., & Schubert, D. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500051h · Cited by 112
Involvement of long noncoding RNAs in diseases affecting the central nervous system
Pastori, C., & Wahlestedt, C. (2012) · RNA Biology · doi:10.4161/rna.20482 · Cited by 100
Dendritic spine dysgenesis in Rett syndrome
Xu, X., Miller, E. C., & Pozzo-Miller, L. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00097 · Cited by 92
“…therapies for the treatment of RTT act on these pathways (highlighted in green, see text for details and references): LM22A-4 binds and activates TrkB receptors directly (Massa et al., 2010); activation of IGF-1 receptors triggers the PI3K and Ras/ERK signaling pathways (Zheng and Quirion, 2004).”
BackgroundA Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease
Todd, D., Gowers, I., Dowler, S. J., Wall, M. D., McAllister, G., Fischer, D. F., Dijkstra, S., Fratantoni, S. A., van de Bospoort, R., Veenman-Koepke, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087923 · Cited by 93
“Literature-reporteded TrkB small molecule agonists tested were amitriptyline [33], 7,8-dihydroxyflavone [36,37], N-acetyl serotonin [35], LM22A-4 [38], and BAG (cyclic peptide [39].”
BackgroundMethodInfluentialNeuroprotection by GDNF in the ischemic brain
Duarte, E. P., Curcio, M., Canzoniero, L. M. T., & Duarte, C. B. (2012) · Growth Factors · doi:10.3109/08977194.2012.691478 · Cited by 102
“Two small molecule BDNF mimetics were recently described, 7,8-dihydroxyflavone and LM22A-4, which activate TrkB neurotrophin receptors (Jang et al. 2010; Massa et al. 2010).”
BackgroundMultiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists
Boltaev, U., Meyer, Y., Tolibzoda, F., Jacques, T., Gassaway, M., Xu, Q., Wagner, F., Zhang, Y.-L., Palmer, M., Holson, E., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aal1670 · Cited by 94
“7,8-DHF (500 nM) LM22A-4 (500 nM) Deoxygedunin (500 nM) Concentration, log (M) % R es po ns e 0 25 75 100 TrkB activation AKT activation ERK1/2 activation EC50 % E R K 1/2 phosphorylation30 60 90 120 0 20 40 60 80 100 % E R K 1/2 phosphorylation −20 0 20 40 60 80 100 120 A C E B D −12 −11 −10 −9 −8 −12 −11 −10 −9 −8 T…”
BackgroundMethodResultInfluentialZuccato, C., & Cattaneo, E. F. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-45106-5_14 · Cited by 100
Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented Subjects
Forlenza, O. V., Miranda, A. S., Guimar, I., Talib, L. L., Diniz, B. S., Gattaz, W. F., & Teixeira, A. L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150172 · Cited by 90
Ye, X., Tai, W., & Zhang, D. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.004 · Cited by 102
Zhang, G., Zhang, T., Li, N., Wu, L., Gu, J., Li, C., Zhao, C., Liu, W., Shan, L., Yu, P., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14102 · Cited by 93
“Althoughmany studies identified that Akt and CREB are downstream targets of BDNF (Massa et al., 2010; Clarkson et al., 2015), a recent study reported that CREB was phosphorylated by Akt, leading to CREB-mediated expression of genes crucial for neuronal survival, including BDNF (Lu et al.”
BackgroundInfluentialCowan‐Jacob, S. W., Jahnke, W., & Knapp, S. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.216 · Cited by 96
Warnault, V., Darcq, E., Morisot, N., Phamluong, K., Wilbrecht, L., Massa, S. M., Longo, F. M., & Ron, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.007 · Cited by 89
Self-citationNamsolleck, P., Boato, F., Schwengel, K., Paulis, L., Matho, K. S., Geurts, N., Thöne‐Reineke, C., Lucht, K., Seidel, K., Hallberg, A., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.008 · Cited by 88
Xiong, Z., Jiang, B., Wu, P., Tian, J., Shi, L., Gu, J. F., Hu, Z., Fu, H., Wang, F., & Chen, J. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.253 · Cited by 91
Understanding cytokine and growth factor receptor activation mechanisms
Atanasova, M., & Whitty, A. (2012) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.729561 · Cited by 96
“…(Cheng et al., 2011), as well as compounds that activate the neurotrophin receptors TrkA (Bruno et al., 2004; Jang et al., 2007), TrkB (Jang et al., 2010; Massa et al., 2010) and TrkC (Chen et al., 2009) (Figure 9) (for a review of small molecule neurotrophin receptor agonists, see Skaper, 2011).”
BackgroundSims, S., Wilken-Resman, B., Smith, C. J., Mitchell, A., McGonegal, L., & Sims‐Robinson, C. (2022) · Neural Plasticity · doi:10.1155/2022/3889300 · Cited by 97
“These four neurotrophins also bind to their low-affinity receptor, p75, which induces apoptosis, and in some cases may promote neuronal survival and neurite growth during neurodevelopment [9].”
BackgroundTelezhkin, V., Schnell, C., Yarova, P., Yung, S., Cope, E. L., Hughes, A., Thompson, B. A. N., Sanders, P., Smith-Geater, C., Hancock, J. M., et al. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00166.2015 · Cited by 90
A small molecule p75NTR ligand protects neurogenesis after traumatic brain injury
Shi, J., Longo, F. M., & Massa, S. M. (2013) · Stem Cells · doi:10.1002/stem.1516 · Cited by 82
Self-citationNeural tissue engineering: Bioresponsive nanoscaffolds using engineered self-assembling peptides
Koss, K. M., & Unsworth, L. D. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.08.026 · Cited by 83
Guerzoni, L. P. B., Nicolas, V., & Angelova, A. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2080-4 · Cited by 81
TrkB inhibition as a therapeutic target for CNS-related disorders
Boulle, F., Kenis, G., Cazorla, M., Hamon, M., Steinbusch, H. W. M., Lanfumey, L., & van den Hove, D. L. A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.002 · Cited by 80
“More recently, using the crystal structure of the BDNF–NT3 heterodimer, the structure of BDNF loop II was further unraveled to generate a pharmacophore, and subsequent in silico screening was performed to identify multiple small nonpeptidic TrkB ligands (Massa et al., 2010).”
BackgroundMethodDrug discovery and the human kinome: Recent trends
Eglen, R. M., & Reisine, T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.007 · Cited by 85
Liu, X., Qi, Q., Xiao, G., Li, J., Luo, H. R., & Ye, K. (2013) · Pharmacology · doi:10.1159/000346920 · Cited by 76
“So far, a few small peptides and compounds have been reported to activate the TrkB receptor and might act as TrkB agonists [24, 25].”
Cardenas-Aguayo, M. D. C., Kazim, S. F., Grundke-Iqbal, I., & Iqbal, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053596 · Cited by 73
“Small molecules that mimic a particular ligand, like in the case of the peptides used in the present study, can bind to their receptors and disrupt protein-protein interactions inhibiting the functions they mediate, or they could act as activating ligands, though there may be differences from the natural ligand with r…”
BackgroundChondroitin sulfate glycosaminoglycan hydrogels create endogenous niches for neural stem cells
Karumbaiah, L., Enam, S. F., Brown, A. C., Saxena, T., Betancur, M. I., Barker, T. H., & Bellamkonda, R. V. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00397 · Cited by 73
Clarkson, A. N., Parker, K., Nilsson, M., Walker, F. R., & Gowing, E. K. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.33 · Cited by 77
Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor
Eibl, J. K., Strasser, B. C., & Ross, G. M. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.10.008 · Cited by 82
“Strategy Mechanism Phase of development Reference(s) NGF agonist Exogenous NGF Upregulate NGF signaling via ligand stimulation of p75NTR and TrkA at site of injection Phase III clinical trial Apfel (2002) NGF gene therapy Transplantation of autologous fibroblast which are genetically modified to express NGF Phase I cl…”
Jin, X., Liu, P., Yang, F.-C., Zhang, Y., & Miao, D. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1088-y · Cited by 72
“Because ERKs play an important role in BDNF regulation [39], and reduced phosphorylation may play a pathological role in depression [40], the present study investigated hippocampal levels of pERK1/2 and BDNF.”
BackgroundHan, J., Pollak, J., Yang, T., Siddiqui, M. R., Doyle, K. P., Taravosh-Lahn, K., Cekanaviciute, E., Han, A., Goodman, J. Z., Jones, B., et al. (2012) · Stroke · doi:10.1161/strokeaha.111.641878 · Cited by 69
Self-citationLocalization of BDNF expression in the developing brain of zebrafish
Felice, E. D., Porreca, I., Alleva, E., de Girolamo, P., Ambrosino, C., Ciriaco, E., Germanà, A., & Sordino, P. (2014) · Journal of Anatomy · doi:10.1111/joa.12168 · Cited by 68
“Deficits in BDNF functions have been associated with different human disorders, such as Alzheimer’s disease, Parkinson’s dis- ease, Huntington’s disease and amyotrophic lateral sclerosis (Frade & L opez-S anchez, 2010; Massa et al. 2010; Laske et al. 2011).”
BackgroundLow molecular weight, non-peptidic agonists of TrkA receptor with NGF-mimetic activity
Scarpi, D., Cirelli, D., Matrone, C., Castronovo, G., Rosini, P., Occhiato, E. G., Romano, F., Bartali, L., Clemente, A. M., Bottegoni, G., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.80 · Cited by 67
Cannavò, A., Jun, S., Rengo, G., Marzano, F., Agrimi, J., Liccardo, D., Elia, A., Keceli, G., Altobelli, G. G., Marcucci, L., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.321583 · Cited by 68
Nomura, T., Musial, T. F., Marshall, J. J., Zhu, Y., Remmers, C. L., Xu, J., Nicholson, D. A., & Contractor, A. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2893-16.2017 · Cited by 64
“Previous studies have demonstrated directly that LM22A-4 crosses the blood– brain barrier after systemic administration by liquid chromatography/tandem mass spectrometry and specifically activates TrkB (Massa et al., 2010; Schmid et al., 2012).”
BackgroundMethodFon, D., Zhou, K. L., Ercole, F., Fehr, F., Marchesan, S., Minter, M. R., Crack, P. J., Finkelstein, D. I., & Forsythe, J. S. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.016 · Cited by 68
“The BDNF-mimetic can mimic trophic effects of the BDNF protein by acting as a TrkB receptor agonist [39], which provides a plausible mechanism for the enhanced neuronal sprouting.”
BackgroundInfluentialNeumann, J. T., Thompson, J. W., Raval, A. P., Cohan, C. H., Koronowski, K. B., & Pérez‐Pinzón, M. A. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.185 · Cited by 66
Гудашева, Т. А., Povarnina, P. Y., Тарасюк, А. В., & Середенин, С. Б. (2020) · Medicinal Research Reviews · doi:10.1002/med.21721 · Cited by 62
“F IGURE 13 Nonpeptide mimetics of BDNF loop 2 with agonistic activity.(111) Compound's codes located under the structures.”
BackgroundTargeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness
Khalin, I., Kocherga, G., Bakar, M. A., & Alyautdin, R. N. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s77480 · Cited by 66
“Moreover, binding with the ligand results in the conversion of the receptor’s monomeric structure into the dimeric form, which is accompanied by autophosphorylation of the intracellular domain.(37) Basically, the TrkB receptor has three core isoforms in the”
Li, R., Liang, T., Xu, L., Zheng, N., Zhang, K., & Duan, X. (2013) · Brain Research · doi:10.1016/j.brainres.2013.05.046 · Cited by 64
“Keap1 functions as a substrate adapter protein for ubiquitination, which causes the proteasomal degradation of Nrf2 (Nguyen et al., 2004; Zhang, 2006).”
Metadata
- Authors
- Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M.
- Affiliations
- University of California, San Francisco (US)
- Stanford University (US)
- University of North Carolina at Chapel Hill (US)
- Medical University of South Carolina (US)
- Banner Sun Health Research Institute (US)
- Corresponding author
- Longo, Frank M.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-05-03
- Volume
- 120
- Issue
- 5
- Pages
- 1774-1785
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2860903
- OpenAlex
- W2055583081
- Cited by
- 406
- References
- 64
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 18 · 2023: 25 · 2022: 22 · 2021: 21 · 2020: 42 · 2019: 22 · 2018: 18 · 2017: 26 · 2016: 23 · 2015: 21 · 2014: 40 · 2013: 41 · 2012: 32
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense (DAMD170310532)
- U.S. Department of Veterans Affairs
- Alzheimer's Association
- Koret Foundation
- Jean Perkins Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- BDNF mimetic, TrkB signaling, brain-derived neurotrophic factor, small molecule agonists, neurotrophic activity, neurodegeneration, traumatic brain injury, Alzheimer's disease, pharmacophore modeling, loop domains, hippocampal neurons, motor learning, neurodegenerative disease therapeutics
- MeSH terms
- Animals, Hippocampus, Kinetics, Male, Mice, Inbred C57BL, Models, Biological, Neurons, Phosphorylation, Protein Binding, Signal Transduction, Rats, Sprague-Dawley, Brain-Derived Neurotrophic Factor, Neurodegenerative Diseases, Receptor, trkB, NIH 3T3 Cells, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.